{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:02Z","timestamp":1787013902157,"version":"build-2736575974"},"reference-count":61,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T00:00:00Z","timestamp":1442793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:p>Flumazenil and naloxone are considered to be pharmacologically ideal antidotes. By competitive binding at the molecular target receptors, they are highly specific antagonists of two important drug classes, the benzodiazepines and opioids, respectively. Both antidotes enjoy rapid onset and short duration after parenteral administration, are easily titrated and are essentially devoid of agonist effects. Yet only naloxone is widely used as a component of the \u2018coma cocktail\u2019, a sequence of empirical treatments to correct altered mental status, while experts discourage the use of flumazenil for such patients. This review contrasts the history, indications, published evidence and novel applications for each antidote in order to explain this disparity in the clinical use of these \u2018ideal\u2019 antidotes.<\/jats:p>","DOI":"10.1111\/bcp.12731","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T08:01:07Z","timestamp":1438934467000},"page":"428-436","source":"Crossref","is-referenced-by-count":75,"title":["Flumazenil, naloxone and the \u2018coma cocktail\u2019"],"prefix":"10.1111","volume":"81","author":[{"given":"Marco L.A.","family":"Sivilotti","sequence":"first","affiliation":[{"name":"Emergency Medicine and Biomedical and Molecular Sciences Queen's University Kingston Ontario"},{"name":"Ontario Poison Centre Hospital for Sick Children Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2009.01.023"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530070060031"},{"key":"e_1_2_6_4_1","first-page":"209","article-title":"Flumazenil\u2013Treatment or toxin. J Toxicol \u2010","volume":"42","author":"Seger DL","year":"2004","journal-title":"Clin Toxicol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02089.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/emj.2010.095075"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2014.10.002"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.63.2.289"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01649_4.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.299.6703.860-b"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6689.1713-a"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6628.1070-e"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(96)70191-9"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.301.6764.1308"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199717030-00004"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120002884"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resuscitation.2006.11.010"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12434"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/PEC.0b013e3182531d0d"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2012.01.059"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008480-199606000-00010"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245201"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.04.007"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31819db2c4"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0b013e3283398ef9"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeu374"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-014-0391-6"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-014-0392-5"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12023"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01649_3.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0022-3565(25)10630-7","article-title":"Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception","volume":"274","author":"Codd EE","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.1998.tb02707.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.1996.tb03487.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/10903127.2011.640763"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098614564776"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1037274"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.3109\/10903127.2014.896961"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2005.tb06550.x"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02724.x"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.09.007"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1202561"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199805000-00004"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199204000-00011"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.2000.tb01260.x"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1197\/aemj.10.8.893"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/10903120903144866"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7386.442"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7044.1435"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2000.tb125633.x"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3959(01)00080-9"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7291.895"},{"key":"e_1_2_6_52_1","first-page":"66","article-title":"Take\u2010home naloxone to prevent fatalities from opiate\u2010overdose: Protocol for Scotland's public health policy evaluation, and a new measure to assess impact","volume":"22","author":"Bird SM","year":"2015","journal-title":"Drugs"},{"key":"e_1_2_6_53_1","first-page":"101","article-title":"Community\u2010based opioid overdose prevention programs providing naloxone \u2010 United States, 2010","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR \u2010 Morb Mortal Wkly Rep"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f174"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-1-201301010-00003"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-261"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.14205"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-14-297"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reaurg.2006.08.002"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjsm.2006.029710"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.2.577"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199901000-00030"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12731","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T18:37:30Z","timestamp":1748543850000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,21]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/bcp.12731"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12731","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,21]]}}}